Active Biotech Enters Clinical Phase IIa Trial with RhuDex

Active Biotech AB and MediGene AG have announced the initiation of a clinical Phase IIa trial of the drug candidate RhuDex for the treatment of rheumatoid arthritis.

The placebo-controlled trial is intended to evaluate the compound's tolerability, to determine the appropriate dosage, and to provide laboratory results with indication of an anti-inflammatory effect of RhuDex.

RhuDex is a novel, orally available substance for the treatment of rheumatoid arthritis, originating from Active Biotech's patented CD80 antagonists and was out-licensed to MediGene's subsidiary Avidex Ltd in 2002.

Upon completion of this trial, an additional Phase II trial with more than 200 patients is scheduled for 2008. MediGene is responsible for the clinical program and carries the related costs.

For further information please contact:

Sven Andréasson,

President and CEO

Tel: +46 46 19 20 49

Email: sven.andreasson@activebiotech.com

Or visit: www.activebiotech.com

Home > News & Events > News > Active Biotech Enters Clinical Phase IIa Trial with RhuDex
Last updated: 2007-03-22

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

ACTIVE BIOTECH AB

ACTIVE BIOTECH AB

Active Biotech is a publicly traded Swedish biotechnology company. The company has five projects in clinical development for the treatment of serious autoimmune/inflammatory diseases and cancer. Laquinimod - a novel oral treatment of multiple sclerosis – is developed through a cooperation with Teva ...